A Randomized Phase II Trial of a Preparative Regimen of Bortezomib, High Dose Melphalan, Arsenic Trioxide and Ascorbic Acid

BACKGROUND: Bortezomib is active for newly diagnosed and relapsed multiple myeloma, and has synergistic activity with melphalan. We conducted a randomized trial to determine the safety and efficacy of adding bortezomib to a preparative regimen of arsenic trioxide (ATO), ascorbic acid (AA) and melpha...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Hoofdauteurs: Sharma, Manish, Khan, Hassan, Thall, Peter F, Orlowski, Robert Z, Bassett, Roland L, Shah, Nina, Bashir, Qaiser, Parmar, Simrit, Wang, Michael, Shah, Jatin J, Hosing, Chitra M, Popat, Uday R, Giralt, Sergio A, Champlin, Richard E, Qazilbash, Muzaffar H
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: 2011
Onderwerpen:
Article
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4015116/
https://ncbi.nlm.nih.gov/pubmed/21887685
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.26517
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items